Crossed eyes (strabismus)
Also known as: Strabismus
Methodology & AI Transparency ⓘ
Crossed eyes (strabismus) Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Cataloged under federal diagnostic code H50.9 in Eyes & Vision, Crossed eyes (strabismus) (also termed Strabismus) requires AREDS2 macular nutrition [Crossed eyes (strabismus) H50.9] so specialists can calibrate treatment intensity against Intraocular Pressure (IOP) [Crossed eyes (strabismus) H50.9] benchmarks.
- 2 Real-world patient consensus: Clinical coding for Crossed eyes (strabismus) uses ICD-10 H50.9 across Eyes & Vision specialty care.
- 3 Typical cash cost range: Differential triage of Crossed eyes (strabismus) (H50.9) utilizes AREDS2 macular nutrition [Crossed eyes (strabismus) H50.9].
- 4 Top reported side effects / signs: Longitudinal Crossed eyes (strabismus) monitoring tracks Intraocular Pressure (IOP) [Crossed eyes (strabismus) H50.9] toward 10 – 21 mmHg (individualized optic target) (H50.9).
Ask our AI Specialists anything about Crossed eyes (strabismus)
What Is Crossed eyes (strabismus)?
Cataloged under federal diagnostic code H50.9 in Eyes & Vision, Crossed eyes (strabismus) (also termed Strabismus) requires AREDS2 macular nutrition [Crossed eyes (strabismus) H50.9] so specialists can calibrate treatment intensity against Intraocular Pressure (IOP) [Crossed eyes (strabismus) H50.9] benchmarks.
Pathophysiology, Underlying Causes & Clinical Presentation
In Crossed eyes (strabismus) (H50.9), physiological disruption stems from microvascular diabetic/hypertensive retinopathy [Crossed eyes (strabismus) H50.9], informing Eye Health, Glaucoma & Vision Disorders protocols that track Best-Corrected Visual Acuity in Crossed eyes (strabismus) (H50.9: & OCT) (Intact retinal nerve fiber & macula (H50.9)).
Common Symptoms & Clinical Signs
- • Presentation of Crossed eyes (strabismus) (H50.9): acute eye redness, in Crossed eyes (strabismus) (H50.9: discharge, photophobia, or)
- • Secondary Crossed eyes (strabismus) clinical sign: gradual blurring, glare/halos in Crossed eyes (strabismus) (H50.9: around nighttime headlights,)
- • Symptom flares in Crossed eyes (strabismus) correlating with Intraocular Pressure (IOP) [Crossed eyes (strabismus) H50.9] deviation outside 10 – 21 mmHg (individualized optic target) (H50.9)
- • Functional eyes & vision impact requiring AREDS2 macular nutrition [Crossed eyes (strabismus) H50.9] evaluation (H50.9)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Crossed eyes (strabismus) Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | H50.9 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Eye Health, Glaucoma & Vision Disorders | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: Intraocular Pressure (IOP) [Crossed eyes (strabismus) H50.9] | 10 – 21 mmHg (individualized optic target) (H50.9) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Best-Corrected Visual Acuity in Crossed eyes (strabismus) (H50.9: & OCT) | Intact retinal nerve fiber & macula (H50.9) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: HbA1c & Systemic in Crossed eyes (strabismus) (H50.9: Blood Pressure) | Microvascular retinal protection (H50.9) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Crossed eyes (strabismus)
Treatment selection for Crossed eyes (strabismus) depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Crossed eyes (strabismus))
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on NOV03 for Signs and Symptoms of Dry Eye Disease Associated With Meibomian Gland: What a 620-Participant Study Found In this randomized controlled trial of patients with DED associated with MGD, NOV03 significantly reduced both signs and symptoms of DED compared with hypotonic saline control. American journal of ophthalmology • 2023-08-15 • Phase III Randomized Trial | N = 620 | 87/100 | PMID 36948372 ↗ |
| New Insights on C5 Inhibitor Avacincaptad Pegol for Geographic Atrophy Due to Age-Related Macular: What a 286-Participant Study Found Intravitreal administration of avacincaptad pegol 2 mg and 4 mg led to a significant reduction of GA growth in eyes with AMD over a 12-month period. Ophthalmology • 2021-04-15 • Phase III Randomized Trial | N = 286 | 87/100 | PMID 32882310 ↗ |
| Can This Approach Help? Inside the Latest Research on Effect of Residual Retinal Fluid on Visual Function in Ranibizumab-Treated Vision outcomes (adjusted for baseline BCVA) through M24 were better in ranibizumab-treated eyes with residual vs resolved SRF, and worse with residual vs resolved IRF. American journal of ophthalmology • 2022-01-15 • Phase III Randomized Trial | Multi-cohort | 82/100 | PMID 34289338 ↗ |
| Can This Approach Help? Inside the Latest Research on Cross-Sectional Analysis of Baseline Visual Parameters in Subjects Recruited Into LHON progresses rapidly in the first months following onset during the subacute phase, followed by relative stabilization during the dynamic phase. Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society • 2021-09-01 • Phase III Randomized Trial | Multi-cohort | 82/100 | PMID 34310464 ↗ |
Crossed eyes (strabismus) Patient Community & “People Like Me” Threads
Filter Crossed eyes (strabismus) community threads and patient logs by age, biological sex, dosage, and treatment duration.